Latest Strategic Partnerships News

Elixir Energy has marked FY26 with major progress in Queensland’s Taroom Trough, expanding contingent gas resources by 32% and securing a strategic $16.6 million capital raise led by Omega Oil and Gas. The company’s operational advances and government backing position it as a key player in Australia’s energy security landscape.

Locality Planning Energy (ASX:LPE) reversed losses to post a $2.31 million statutory profit in FY2026, driven by strategic acquisitions, improved earnings, and a strengthened balance sheet.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

Immuron Limited posted a 6% rise in FY26 sales to $7.7 million, improved its net loss by $1.4 million, and secured FDA approval for IMM-529, underpinning a strategic pivot towards profitability and geographic expansion.

Saluda Medical delivered FY26 revenue of US$90.2 million, beating guidance with strong US and international growth, while reporting a flat net loss of US$149.6 million amid ongoing heavy investment. The company’s FDA approval of its CAP24 paddle lead opens a new US surgical market segment.

Weebit Nano surged to record revenue of $15.3 million in FY26, fueled by key licensing deals and product tape-outs, while investing heavily in R&D and AI initiatives. Despite a $54.9 million loss, a $102 million capital raise leaves the company well-positioned for growth.

Talius Group’s HY2026 results reveal a strategic pivot towards higher-margin software subscriptions, with gross margin surging to 51% despite a 19% revenue dip due to hardware deployment timing. Active subscriptions topped 53,200, underpinning a $3.26 million ARR, while cash burn shrank dramatically.

NobleOak Life delivered robust FY26 results with in-force premiums climbing 18% to $549.2 million and underlying NPAT up 15%, driven by strong market share gains and operational efficiency.

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.

Associate Global Partners (ASX:APL) reported a 20% rise in funds under management to $1.672 billion for FY2026, driven by strong inflows and new partnerships with Muzinich and ARK Invest.